证券代码：603387 证券简称：基蛋生物 公告编号：2025-030 基蛋生物科技股份有限公司 第四届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 基蛋生物科技股份有限公司（以下简称"公司"）第四届监事会第七次会议的通知 已于2025年8月18日以电子邮件的方式发出，通知了全体监事和其他列席人员。公司本 次监事会会议于2025年8月29日以现场及通讯表决方式召开。会议应出席监事3人，实际 出席监事3人。会议由监事会主席李靖召集和主持，公司董事会秘书和财务负责人列席 了本次监事会会议。本次会议的召开符合《中华人民共和国公司法》和《基蛋生物科技 股份有限公司章程》及有关法律法规的规定，会议决议合法有效。 二、监事会会议审议情况 （一）审议并通过《关于公司〈2025年半年度报告〉及其摘要的议案》 公司根据2025年半年度的实际经营情况和财务状况，依照有关规定编制《2025年半 年度报告》及其摘要。 具体内容详见公司同日在上海证券交易所网站(www.sse.com.cn)及《上 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2025-029 基蛋生物科技股份有限公司 第四届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 基蛋生物科技股份有限公司（以下简称"公司"）第四届董事会第七次会议的通知 已于 2025 年 8 月 18 日以电子邮件形式向全体董事发出。本次会议于 2025 年 8 月 29 日 以现场及通讯表决方式召开。会议应出席董事 9 人，实际出席董事 9 人。本次会议由董 事长苏恩本先生主持，公司全体监事和高级管理人员列席了本次会议。本次会议的召开 符合《中华人民共和国公司法》和《基蛋生物科技股份有限公司章程》及有关法律法规 的规定，会议决议合法有效。 二、董事会会议审议情况 （一）审议并通过《关于公司〈2025 年半年度报告〉及其摘要的议案》 公司根据 2025 年半年度的实际经营情况和财务状况，依照有关规定编制《2025 年 半年度报告》及其摘要。董事会审核后认为公司编制的 2025 年半年度报告及其摘要， 可以全面、客观、 ...

Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on September 15, 2025, at 14:00 [1] - The meeting will take place at the fourth-floor conference room of the company located at No. 9, Bofu Road, Yangtze River Industrial Development Zone, Liuhe District, Nanjing [1] - Voting will be conducted through a combination of on-site and online methods using the Shanghai Stock Exchange's network voting system [1] Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange network voting system from 9:15 to 15:00 on the day of the meeting [1][2] - Specific voting times include trading hours: 9:15-9:25, 9:30-11:30, and 13:00-15:00 [1] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts [4] Shareholder Participation - Only shareholders registered by the close of trading on September 8, 2025, are eligible to attend the meeting [6] - Shareholders can appoint proxies to attend and vote on their behalf, with specific documentation required for both representatives and proxies [5][6] Notification Services - The company will utilize a reminder service provided by Shanghai Stock Exchange Information Network Co., Ltd. to notify shareholders about the meeting and voting [3][4] - Notifications will be sent via smart SMS to ensure that small and medium investors can participate [3]

Group 1 - The company held its fourth board meeting on August 29, 2025, where it approved the proposal to revise and establish corporate governance-related systems [1] - The revisions and new systems are aimed at standardizing company operations in accordance with the Company Law and Securities Law of the People's Republic of China, as well as the revised Articles of Association [1] - The proposed systems will be submitted for shareholder meeting approval, with the first seven items requiring such approval [1][2] Group 2 - The company has disclosed the details of the revised and newly established governance systems on the Shanghai Stock Exchange website and in the Shanghai Securities Journal [1]

一、资产减值准备的计提概况 证券代码：603387 证券简称：基蛋生物 公告编号：2025-035 基蛋生物科技股份有限公司 关于 2025 年半年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为客观、公允、准确地反映基蛋生物科技股份有限公司（以下简称"公司"） 截至 2025 年 6 月 30 日的资产状况和 2025 年半年度的经营成果，根据《企业会 计准则》和公司会计政策相关规定，基于谨慎性原则，公司对截至 2025 年 6 月 将相关情况公告如下： 项目 确定组合的依据 本公司对单项金额在初始确认后已经发生信用减值的应收账款、其他应收款 单独确定其信用损失。 为客观、公允、准确地反映公司财务状况和经营成果，根据《企业会计准则》 和公司相关会计政策的相关规定，基于谨慎性原则，公司对截至 2025 年 6 月 30 日的各项资产进行了减值迹象的识别和测试，并根据识别和测试的结果，计提了 相关资产的减值准备。公司 2025 年 1-6 月对各项资产计提减值准备合计为 当在单项工具层面无法以合理成本 ...

Core Viewpoint - The company is actively implementing the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan to enhance corporate governance, innovation capabilities, and investor communication while ensuring sustainable returns for investors [1][6]. Group 1: Focus on IVD Main Business and Operational Quality - The company aims to become a globally competitive biotechnology firm by focusing on the IVD sector, expanding its product lines from low-throughput to high-throughput and automated systems, covering various testing fields [1]. - The company has established eight technology platforms and has expanded its overseas market presence to 130 countries, with overseas product revenue reaching 0.73 billion, a year-on-year increase of 45.42% [1]. - The revenue from the chemical luminescence product line reached 1.50 billion, a year-on-year increase of 10.64%, accounting for 33.54% of the company's self-produced product revenue [1]. Group 2: Increased R&D Investment and Innovation Capability - The company has increased its R&D investment to 0.88 billion in the first half of 2025, representing 17.24% of its operating income, focusing on developing differentiated products based on clinical needs [2]. - As of June 30, 2025, the company holds 383 effective patents, including 57 invention patents, 296 utility model patents, and 30 design patents [2]. - The company follows a "produce one generation, research one generation, reserve one generation" strategy to enhance its R&D capabilities and product innovation [2]. Group 3: Enhanced Corporate Governance and Compliance - The company is revising its governance structure by abolishing the supervisory board and transferring its responsibilities to the audit committee, pending approval at the 2025 first extraordinary general meeting [3]. - The company emphasizes the importance of internal control effectiveness and regularly evaluates its governance structure to ensure compliance with laws and regulations [4][5]. Group 4: Strengthened Investor Communication - The company is committed to transparent information disclosure and actively engages with investors through various channels, including performance briefings and visual reports on its official platforms [4]. - The company has established a dedicated investor relations email and hotline to facilitate ongoing communication with investors [4]. Group 5: Continuous Cash Dividends and Investor Return Mechanism - The company completed a cash dividend distribution of 0.9 yuan per 10 shares on June 17, 2025, totaling approximately 45.64 million, with cumulative cash dividends and buybacks exceeding 8.51 billion since its IPO [5]. - The company plans to maintain a stable cash dividend strategy and develop reasonable profit distribution plans to reward investors [5]. Group 6: Ongoing Evaluation of Action Plan - The company will continue to advance and assess the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan while fulfilling its information disclosure obligations [6].

Group 1 - The company plans to abolish the supervisory board and amend its Articles of Association to enhance governance structure and operational standards [1][2] - The supervisory functions will be transferred to the audit committee under the board of directors, in compliance with relevant laws and regulations [1][2] - The proposal to abolish the supervisory board will be submitted for approval at the shareholders' meeting [1] Group 2 - The company will revise the relevant clauses in its Articles of Association, including the definition of stakeholders to include employees [2][3] - The company is registered in Nanjing and operates under the unified social credit code [3][4] - The Articles of Association will serve as a legally binding document governing the rights and obligations between the company, shareholders, and management [6][11] Group 3 - The company’s business scope includes various technical services, medical device production, and sales [7][8] - The company’s shares are to be issued based on principles of fairness and equality, ensuring equal rights for all shareholders [17][18] - The company has specific provisions regarding the acquisition of its own shares, which require shareholder approval under certain conditions [24][25]

Core Viewpoint - The company, Getein Biotech, is holding an online investor presentation on September 10, 2025, to discuss its 2025 semi-annual performance and financial results, allowing for interactive communication with investors [1][2]. Group 1: Meeting Details - The investor presentation is scheduled for September 10, 2025, from 14:00 to 15:00 [2][3]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center, accessible via the website [1][2]. - The format of the meeting will be an online interactive session [2][3]. Group 2: Participation Information - Investors can submit questions from September 3, 2025, to September 9, 2025, before 16:00 through the Roadshow Center website or via the company's email [2][3]. - The presentation will include responses to commonly asked questions from investors [2][3]. Group 3: Participants - Key participants in the meeting will include the Chairman and General Manager, Su Enben, the Chief Financial Officer, Ni Wen, and the Board Secretary, Liu Cong, along with independent directors [2].

证券代码：603387 证券简称：基蛋生物 公告编号：2025-038 基蛋生物科技股份有限公司 关于聘任证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 基蛋生物科技股份有限公司（以下简称"公司"）原证券事务代表谢玉鑫先 生因工作变动，向董事会递交辞呈，提请辞去公司证券事务代表职务。谢玉鑫先 生在担任公司证券事务代表期间恪尽职守、勤勉尽责，董事会对其在任期间为公 司作出的积极贡献表示衷心的感谢！ 公司于2025年8月29日召开第四届董事会第七次会议，审议通过了《关于聘 任证券事务代表的议案》，公司董事会同意聘请王娇女士为公司证券事务代表， 协助董事会秘书履行职责。任期自本次董事会审议通过之日起至第四届董事会届 满为止。王娇女士已取得上海证券交易所董事会秘书任职培训证明，具备履行职 责所必需的专业能力，其任职资格符合《上海证券交易所股票上市规则》等相关 规定。 公司证券事务代表的联系方式如下： 电话：025-68568577 电子邮箱：IR@getein.cn 联系地址：南京市六合区沿江工业开发区博富路9号 ...

Core Points - The audit committee of the company is established to enhance the decision-making function of the board and ensure effective supervision of the management [1][2] - The audit committee consists of three members, including two independent directors, with a professional accountant serving as the chairperson [2][3] - The main responsibilities of the audit committee include supervising external and internal audits, reviewing financial reports, and assessing the effectiveness of internal controls [3][5] Group 1 - The audit committee is responsible for evaluating external audit work and proposing the hiring or replacement of external audit firms [3][10] - The committee must approve financial disclosures and significant accounting changes before submission to the board [5][6] - The committee has the authority to investigate unusual business conditions and can hire external professionals for assistance if necessary [3][12] Group 2 - The audit committee meetings must be convened with at least two-thirds of the members present to make decisions [10][11] - The committee is required to maintain confidentiality regarding the matters discussed in meetings [14] - The rules governing the audit committee's operations are subject to national laws and regulations, and any conflicts will be resolved in favor of the latter [14][36]